Lyell Immunopharma, Inc. LYEL

Full chart Compare
Set alert

Price alert · LYEL

All alert types
15.00 USD -0.43 (-2.79%)

At closeNov 5, 2026, 5:34 PM EST

15.26 +0.26 +1.73%

After hours · Nov 5, 5:34 PM ET

13.69 Day range 16.20
7.20 52-week range 45.00
YTD
-51.27%
1 year
-9.31%

Analyst view

Consensus: hold

Hold
Price target (mean) 1.00
Ratings (0m) 4 0 buy · 3 hold · 1 sell
  • Strong buy0
  • Buy0
  • Hold3
  • Sell0
  • Strong sell1

Recommendation trend

  • This month 4
  • 1 month ago 4
  • 2 months ago 4
  • 3 months ago 4

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

LYEL analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.13-0.13 – -0.13-0.1737+25.2%0-100.0%1
Next quarter0.000.00 – 0.000.000.0%00.0%0
Current year-0.58-0.58 – -0.58-0.707+18.0%27.33K-79.0%1
Next year-0.45-0.45 – -0.45-0.58+22.4%0-100.0%1

Upgrades and downgrades

The latest rating changes

LYEL analyst upgrades and downgrades
DateFirmActionFromTo
Nov 12, 2024HC Wainwright & Co.ReiteratedNeutralNeutral
Oct 30, 2024B of A SecuritiesDowngradeBuyUnderperform
Oct 28, 2024HC Wainwright & Co.ReiteratedNeutralNeutral
Aug 19, 2024HC Wainwright & Co.ReiteratedNeutralNeutral
Jun 27, 2024B of A SecuritiesMaintainedBuyBuy
Jun 27, 2024HC Wainwright & Co.DowngradeBuyNeutral
May 7, 2024HC Wainwright & Co.ReiteratedBuyBuy
Feb 29, 2024HC Wainwright & Co.MaintainedBuyBuy
Nov 9, 2023HC Wainwright & Co.MaintainedBuyBuy
Aug 28, 2023JP MorganDowngradeOverweightNeutral
May 5, 2023HC Wainwright & Co.Reiterated—Buy
Mar 2, 2023HC Wainwright & Co.Maintained—Buy
Jan 24, 2023Morgan StanleyMaintained—Equal-Weight
Nov 14, 2022Morgan StanleyDowngradeOverweightEqual-Weight
Nov 11, 2022Goldman SachsDowngradeBuyNeutral
Oct 17, 2022HC Wainwright & Co.Initiated—Buy
May 24, 2022Goldman SachsMaintained—Buy
Mar 31, 2022Goldman SachsMaintained—Buy
Jan 6, 2022Morgan StanleyMaintained—Overweight
Jul 12, 2021Morgan StanleyInitiated—Overweight
Jul 12, 2021B of A SecuritiesInitiated—Buy
Jul 12, 2021JP MorganInitiated—Overweight
Jul 12, 2021Goldman SachsInitiated—Buy